Regenexx Reports Outcomes of Stem Cell Research Study for Osteoarthritis Treatment

Denver, Colo.-based Regenexx, a nationwide network of doctors specializing in regenerative medicine and advanced interventional orthopedic techniques, has released results of a peer-reviewed research study of 840 patients treated for knee osteoarthritis. All patients were treated using precise imaging guidance and the patented Regenexx protocol, which obtains stem cells from the patient’s own bone marrow.

Regenexx is an extension of the Centeno-Schultz clinic.

“We’re proud to say that this study represents the largest published human experience with stem cell injections to treat knee arthritis to date,” said Christopher Centeno, M.D., the company’s CEO. “No group has published more data on same day stem cell procedures to treat common orthopedic conditions without surgery.”

The research study on knee arthritis examined the efficacy and safety of bone marrow and bone marrow plus fat stem cell injections. Most of the study patients were knee replacement candidates. Many patients in the study were able to avoid knee replacement. Self-rated functional and pain scores all showed statistically significant positive changes from baseline in both treatment groups. The study concluded that there was no advantage of adding fat to the joint over just bone marrow stem cells. Safety in both groups was excellent compared to knee replacement, Regenexx claims.

These studies represent data collected in the Regenexx registry as patients were treated; the data were not collected as part of a randomized controlled trial of the type commonly used in drug studies. The company has 3 such RCTs that it has funded. One knee osteoarthritis study being conducted in Chicago has completed enrollment, while the other studies for shoulder rotator cuff tears and ACL tears are open and still recruiting in Colorado.